Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercialization Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercialization